

Effect of Methotrexate and Linoleic Acid on BAX/BCL2 Ratio in Human Hepatocyte Cell

ABSTRACT

Aims: To investigate the effect of methotrexate and linoleic acid on BAX/BCL 2 ratio in human hepatocyte cell.

Study design; Original Research Article.

Place and Duration of Study: The study was carried out in partnership with the Department of Anatomy and Department of Medical Pharmacology of Çukurova University Faculty of Medicine, using the laboratory facilities of the Department of Medical Pharmacology.

Methodology: Human hepatocyte cell line (CRL-11233) cells obtained from the American Type Culture Collection Organization (ATCC) were used. Expressions of apoptotic pathway markers, apoptosis inducing factor BAX, BCL2 and BAX/BCL2 were evaluated. All analyzes were examined in four groups (Group 1; control, Group 2; linoleic acid given, Group 3; methotrexate given and Group 4; linoleic acid and methotrexate given).

Results: The mean \pm standard error values of the obtained results as nanogram / milliliter (ng / ml) are in Group I, Group II, Group III and Group IV, respectively; BAX values, 0.900 ± 0.1864 , 1.002 ± 0.2098 , 8.352 ± 1.467 and 4.295 ± 1.522 , BCL 2 values, 13.93 ± 1.198 , 13.92 ± 1.739 , 2.938 ± 1.059 and 9.250 ± 1.492 and BAX/BCL2 values 0.065, 0.072, 2.843 and 0.464.

Conclusion: While BAX/BCL2 level increased in the group given methotrexate, it decreased in the group given linoleic acid and methotrexate.

Keywords: BAX/BCL2, hepatocyte, liver, linoleic acid, methotrexate.

1. INTRODUCTION

The liver is the target organ for drug toxicity as it is responsible for the metabolism of many foreign substances due to its location in the gastrointestinal tract. The incidence of drug-induced liver injury in general populations is about 14-19 per 100,000 people. The reported incidence and severity of drug-induced liver injury varies among drugs, suggesting that drug properties have a role in drug-induced liver injury risk determination. Conversely, drugs with drug-induced liver injury potential cause liver injury only in a small portion of patients indicating that host factors play a major role in drug-induced liver injury development [1]. Hepatotoxicity has a considerable impact on health because many of the hepatic reactions induced by pharmaceutical preparations can be very severe. Drug-induced organ toxicity is a frequently encountered obstacle in the field of medical practice that limits the use of numerous pharmacologically valuable drugs. Drugs are an important cause of liver injury. More than 900 drugs, toxins, and herbs have been reported to cause liver injury, and drugs account for 20-40% of all instances of fulminant hepatic failure. Approximately 75% of the idiosyncratic drug reactions result in liver transplantation or death. Antituberculosis drugs, methotrexate, niacin, vitamin A, antiandrogens can be given as examples of drugs that increase the risk of hepatotoxicity in chronic liver disease. Methotrexate (MTX)-induced organ toxicity is unfortunately the rate-limiting factor for its clinical application. The clinical use of MTX is significantly limited due to the associated various organ toxicities, including kidney, liver, lung, bone marrow, and gastrointestinal toxicities [1-2]. Methotrexate is a folic acid antagonist with anti-inflammatory and immunosuppressive effects [3]. It is used in the treatment of ALL, the treatment of meningeal carcinomatosis, the prophylaxis and treatment of meningeal leukemia and lymphoma, the combination therapy of non-hodging lymphomas, the adjuvant therapy of osteosarcoma, the treatment of rheumatoid arthritis, resistant psoriasis, and also in the treatment of breast, head-neck, ovary and bladder cancer [4-6]. In

34 addition, MTX has been the most commonly used immunosuppressive agent after prednisolone in the treatment of
35 various skin diseases by dermatologists for more than fifty years. It is cheap, has a reducing effect on steroid dose, is well
36 known about its toxicity and side effects, and the availability of efficacy data has increased its use in dermatology [7]. MTX
37 side effects that occur during treatment are quite common. Generally, these side effects resolve after the end of treatment
38 or dose reduction. Approximately 30% of the patients who receive MTX treatment are discontinued due to drug toxicity [8].
39 For this reason, it comes to the conclusion that it should be used together with antioxidants to avoid MTX toxicity. In the
40 literature, melatonin, nicotinamide, methionine, vitamin E and n-acetylcysteine, alpha lipoic acid, lipoic acid, vitamin C,
41 melatonin, coconut, folic acid, antioxidant agents, anti-inflammatory and vasodilator agents have been tried to protect
42 tissues from MTX damage [9-17]. Also, studies on molsidomine, inulin, coconut, improved metformin, misoprostol, vitamin
43 E, Indole-3-Carbinol, balanites aegyptiaca extract, melatonin and ursodeoxycholic acid, sitagliptin, silymarin, turmeric and
44 naringin to prevent hepatotoxicity caused by MTX are available [14,17-26]. We think that linoleic acid (LA) can be able to
45 reduce the BAX/BCL2 ratio and prevent apoptosis. The hypothesis of our study is that linoleic acid prevents hepatotoxicity
46 and MTX caused hepatotoxicity. LA has anticarcinogenic effects on human metabolism, enhancing the immune system,
47 lowering cholesterol, lowering the risk of arteriosclerosis, promoting development and growth, reducing fat accumulation in
48 the body, protecting against diabetes, enhancing muscle growth, eliminating free radicals, antibacterial and antioxidative
49 effects [27]. The aim of our study is to investigate the effect of methotrexate and linoleic acid on BAX/BCL 2 ratio in
50 human hepatocyte cell.

51 52 **2. MATERIAL AND METHODS**

53 54 **2.1 Experimental Design**

55 In this study, human hepatocyte (CRL-11233) cells obtained from the American Type Culture Collection Organization
56 (ATCC) were used. All experimental procedures have been approved by "Non-Invasive Clinical Research Ethics
57 Committee of Çukurova University Faculty of Medicine for our study (Decision No: 104/9). This study is derived from the
58 Anatomy Doctor of Philosophy program thesis supported by Çukurova University Research Fund (project no: TDK-2018-
59 10773). All the test procedures were performed after ethics committee approval according to the Helsinki Declaration of
60 Principles and and the measures were done in Cukurova University Faculty of Medicine, Department of Medical
61 Pharmacology. Cell lines were randomly divided into four groups (6 cell lines per group) as follows;

62 Group I; Healthy control group. No substance was given to this group.

63 Group II; Only MTX in liquid form has been given to this group.

64 Group III; Only LA has been given to this group.

65 Group IV; MTX + LA was given to this group.

66 **2.2 Experimental process;**

67 BAX, BCL-2, apoptotic mediators were examined by ELISA test.

68 **2.2.1 ELISA (Enzyme Linked Immunosorbent Assay) Test**

69 Expressions of apoptotic pathway mediators AIF, BAX, BCL-2, GADD153, GRP78 and CASPASE-3 were analyzed by
70 ELISA test (Awareness Technology Inc., ChroMate Elisa Reader, US). As a result of protein quantification, 25 µl of each
71 standard and samples were added to the ELISA plate and 200 µl (working reactant = 50A solution: 1 B solution) was
72 added to the plate and the plate was shaken in a shaker for 3 seconds, and then it was incubated at 37 degrees for 30
73 minutes and read on the spectrophotometer at 562 nm.
74

75 76 **2.3 Statistical analysis**

77 Relaxation responses of tissues were expressed as a percentage of contractions. It is shown with standard errors.
78 GraphPad Prism 8.1.2 for drawing graphs and for statistical analysis. (CA, USA) program was used. One way (ANOVA)

79 and post-hoc test (Bonferroni method) were used for statistical comparisons. The results were evaluated at a 95%
80 confidence interval.

81 82 3. RESULTS

83
84 When the expression levels of BAX, BCL2 were examined, it was found that LA had a protective effect on MTX-induced
85 hepatotoxicity (Table 1).


86 **Table 1. Effects of Methotrexate (MTX) and Linoleic Acid (LA) on human liver hepatocyte cells**

	Group I	Group II	Group III	Group IV
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
	(min-max)	(min-max)	(min-max)	(min-max)
BAX	0.900±0.1864 (0.6500-1.120)	1.002±0.2098 (0.7500-1.300)	8.352±1.467 (5.900-10.42)	4.295±1.522 (2.500-6.120)
BCL2	13.93±1.198 (12.80-16.10)	13.92±1.739 (11.80-16.50)	2.938±1.059 (1.770-4.200)	9.250±1.492 (7.700-11.60)
BAX/BCL2	0,065	0,072	2,843	0,464

87 (n=6, ANOVA, Post hoc: Bonferroni). SD; Standard Deviation, Min; Minimum, Max; Maximum.

88

89



90

91 **Figure 1. Distribution of BAX apoptotic marker among groups**

92




Figure 2. Distribution of Bcl-2 apoptotic marker among groups

In the study where we examined the effect of LA and MTX on hepatocyte cell. The changes in the values of BAX, BCL2 between the groups, respectively, in the control group; 0.900 ± 0.1864 ng/ml, 13.93 ± 1.198 ng/ml, in the LA group; 1.002 ± 0.2098 ng/ml, 13.92 ± 1.739 ng/ml, in the MTX group; 8.352 ± 1.467 ng/ml, 2.938 ± 1.059 ng/ml, in the group receiving LA +MTX; 4.295 ± 1.522 ng/ml, 9.250 ± 1.492 ng/ml were found (Figure 1, Figure 2). When BAX expression is compared to the control group; It increased in Group II, III, IV. However, it was determined that the highest increase was only in the MTX group. BCL2 expression when compared to the control group; It decreased in the MTX group. It was found to be increased in the group given MTX and LA compared to the group given MTX and in the group given only LA. When the expression levels of markers were examined, it was concluded that hepatotoxicity was induced in the MTX given groups.

4. DISCUSSION

Drugs were held responsible for more than 50% of liver disease. MTX, an antineoplastic drug, belongs to the group of antimetabolites. It acts as a folic acid antimetabolite [4]. There are many studies in the literature about pure squamous cell cancer of the urinary tract [28], in cancer types [29], rheumatoid arthritis [30] in dermatology [31] where methotrexate is used. MTX creates side effects, especially nephrotoxicity and hepatotoxicity, against these wide indications for use. These side effects are thought to be the result of oxidative damage caused by reactive oxygen species. In addition, other toxic effects of MTX are neurotoxicity, pulmonary fibrosis, testicular toxicity, pancreatic toxicity and intestinal mucositis [32-34]. There are studies in the literature to prevent hepatotoxicity and nephrotoxicity, which are the most important side effects caused by MTX [16,33,34]. In this study, the effect of LA, which has anticarcinogenic, antimutagenic, anti-inflammatory and fat mass reducing effect, to prevent hepatotoxicity caused by MTX was investigated. LA has skin barrier, immune, cardiovascular, neurobiological, reproductive, thermoregulatory and digestive functions [35]. However, although there are many studies on experimental animals the number of studies examining the effects of LA on human metabolism is very few.

In the study where we examined the protective effect of LA against hepatotoxicity induced by MTX, apoptotic markers were examined and evaluated. Apoptotic markers; BAX; Group I (Control); 0.900 ± 0.1864 ng / ml, only in Group II with LA application; 1.002 ± 0.2098 ng / ml, only in Group III with MTX application; In Group IV where 8.352 ± 1.467 ng / ml and LA + MTX was applied; It was found to be 4.295 ± 1.522 ng / ml. When BAX expression is compared to the control group; It increased in Group II, III, IV. However, the highest increase was seen only in Group III, where MTX was applied. Also, BCL 2; Group I (Control); 13.93 ± 1.198 ng / ml, only in Group II with LA application; 13.92 ± 1.739 ng / ml, only in Group III with MTX application; In Group IV where 2.938 ± 1.059 ng / ml and LA + MTX was applied; It was found to be $9,250 \pm 1,492$ ng / ml. BCL-2 expression when compared to the control group; It decreased in the MTX group. It increased in the group given MTX and LA compared to the group given MTX and in the group given only LA. While the BAX/BCL2 ratio was similar between the LA group and the control group, a significant increase was observed in the MTX group. In the MTX+LA group, the BAX/BCL2 ratio decreased compared to the MTX-administered group.

BAX, BCL2 and the BAX/BCL2 ratio are apoptotic markers that are frequently evaluated in the literature. In their study on mice, Ge et al., examined the protective effect of tempol against acute hepatotoxicity caused by acetaminophen and found that it reduced pro-apoptotic protein expressions BAX and increased anti-apoptotic BCL2 [36]. In another study examining the preventive effect of Nigella Sativa oil in mice against apoptosis and hepatotoxicity caused by the galactose-induced aging process, they found that the level of BAX protein increased in the group treated with D-galactose and no

change was observed in the level of BCL2 protein. Therefore, the ratio of BAX / BCL2 increased significantly and decreased from 1.34 ± 0.15 to 0.75 ± 0.19 in the group given black seed oil (0.1ml / kg) compared to the group treated with D-galactose ($P < 0.001$) [37]. Yang et al. investigated the protective effect of the polysaccharide D-Isosulfuridocide obtained from *Laurencia undulata* on alcohol-induced hepatotoxicity in HepG2 cells, and found that decrease in BAX and BCL2 proteins in the group given D-Isosulfuridocide [33]. Zhang et al. investigated the protective effect of aspirin on acute liver injury due to paraquat in rats, and found that BAX value decreased, BCL2 value increased after aspirin treatment [38]. In a study by Ramachandran et al., examined the effect of acetaminophen hepatotoxicity on mitochondrial oxidative stress, DNA and liver damage, they found an increase in BAX values [39]. Similarly, Kouam et al., investigated the protective effect of *Khaya grandifoliola* (Meliaceae) used in Cameroon traditional medicine to prevent acetaminophen-induced hepatotoxicity. They found a decrease in BAX value in the group treated with *Khaya grandifoliola* [40]. In another study conducted on mice to prevent acetaminophen-induced hepatotoxicity, the protective effect of *Folium Microcos* was examined, and increase BAX value and decrease in BCL2 were observed in the acetaminophen given group compared to the acetaminophen + *Folium Microcos* group [41]. In another study examining the effect of vitamin E and Metallothionein in fish to prevent the toxicological effect of cadmium on the liver, increase in BAX value was found in the group given saline compared to the group given vitamins and Metallothionein [42]. Hamed et al. examined the protective effect of strawberries against hepatotoxicity due to carbon tetrachloride and found that BAX value decreased and BCL2 value increased in the group receiving strawberries [43]. In the study conducted by Orazizadeh et al., who examined the effect of glycyrrhizin acid on BAX and BCL2 expression in hepatotoxicity caused by Titanium dioxide nanoparticles in rats, they found that increase in BAX expression and decrease in BCL2 expression [44].

In a study conducted with a lung cancer cell line examining the effect of linoleic acid on the expression of apoptotic genes in lung cancer, decrease in BAX level and increase in BCL2 level were found as a result of 72-hour LA treatment [45]. In another study examining the effect of LA supplementation on in vitro maturation, embryo development and apoptotic related gene expression in sheep, it was reported that increase in the mRNA expression of the BAX (BCL2, associated X) gene in the group given LA compared to the control group [46]. A study mouse cell line HEP2G with liver cancer demonstrated the antiproliferative effect of LA by inducing apoptosis mediated by upregulation of BAX and downregulation of BCL2 [47]. In a study in which HepG2 and Hep3B cell lines were used to investigate the effects of LA on cell viability and cell proliferation ability, it was observed that in the HepG2 cell line, there was increase in BAX level and decrease in BCL 2 level in the group given LA compared to the control group [48]. In a study evaluating visceral adipose tissue in mice without thymus gland, mice given the stearic acid diet were found to have significantly less belly fat compared to mice given LA, lower BCL2 levels and higher level of BAX [49]. Similarly, in a study involving the monitoring of dorsal adipose fat ratio in pigs, it was found that there was decrease in BCL 2 level and increase in BAX level in the group given LA [50].

In the another study examining the protective effects of *Moringa oleifera* leaf extract against oxidative stress and apoptosis in the liver and kidney due to MTX in mice, the BAX value was found to be higher in the MTX group compared to the group receiving *Moringa* + MTX, while the BCL2 value was found to be lower [51]. In the study of Samdanci et al., they examined the protective effect of molsidomine against MTX-induced hepatotoxicity in rats, they found that the BCL 2 ratio was higher in the group given only MTX compared to the molsidomine + MTX group [17]. In the study of Kalantari et al., investigating the effect of inulin to prevent MTX-induced hepatotoxicity in mice, they stated that MTX administration caused significant liver damage in all mice and found decrease in BCL2 value compared to the control group [52]. In a study by Abo-Haded et al., examined the protective effect of sitagliptin to prevent MTX-induced hepatotoxicity in mice, found that increase in the immuno-expression of the pro-apoptotic protein BAX level and decrease in anti-apoptotic BCL2 level in the MTX-treated group [23]. Tabatabaei et al., investigated the neuroprotective effects of CU and LLLT on the BAX/BCL2 expression ratio in PC12 Cells induced by 6-OHDA. They found the combination of LLLT and CU has a neuroprotective effect on PC12 cells against 6-OHDA-induced neurotoxicity due to an increase cell viability and decrease an increase in the Bax/Bcl2 ratio which shows cell susceptibility to apoptosis [53]. In another study, the expression of apoptotic genes including BAX and BCL2 was evaluated in B16-F10 melanoma cancer and L929 cells by real-time PCR assay. As results shows in study, the expression of all genes and the BAX/BCL2 ratio were significantly changed after CAP treatment in B16-F10 tumor cells in comparison to untreated controls (BAX ($P = 0.028$), BCL2 and CASP3 ($P = 0.014$), and BAX/BCL2 ($P < 0.0001$)). CUR significantly changed the mRNA expression of BCL2 in B16-F10 tumor cells in comparison to untreated control cells (BCL2 ($P = 0.039$)). However, the BAX gene did not significantly increase in the CUR-treated cells, and BAX/BCL2 ratio was significantly increased in B16-F10 tumor cells ($P < 0.0001$). The expression of BAX ($P = 0.034$), BCL2 ($P = 0.042$), and BAX/BCL2 ratio ($P < 0.0001$) was found significantly altered after combination therapy in B16-F10 cells in comparison with untreated cells. CAP and CUR treatments were found had no significant effects on the expression of apoptotic genes in L929 normal cells [54].

Our study findings have resulted in support of the literature. In our study, it was found that MTX biochemically significantly increased liver apoptotic marker BAX protein level compared to the control group. However, in the group which LA + MTX was used, it was observed that decrease in these protein value compared to the group using MTX. This

190 result of our study also supports the positive effect of LA on hepatocyte apoptosis. At the BCL2 protein level, it was found
191 that the apoptotic effect of MTX on hepatocyte cells decreased. But BCL2 protein level increased in the LA + MTX group.
192 MTX-associated toxicities have a multifactorial history, meaning they occur through a combination of genetic and
193 environmental factors. The pharmacological metabolism of MTX includes many transporters and enzymes that can affect
194 the efficacy and toxicity of MTX. We think that small differences between studies are also caused by these reasons. In
195 addition, we think that factors such as cell line usage, clinical applications, use of experimental animals, ethnic origin,
196 difference and amount of active ingredients will affect the study results.

197 5. CONCLUSION

- 198 • When the expression levels of these markers were examined, it was concluded that LA had a protective effect on
199 MTX-induced hepatotoxicity.
- 200 • It has been demonstrated that LA supplementation can be used to prevent hepatotoxicity in patients.
- 201 • We recommend that, these studies be continued with different supplements aimed at preventing the hepatotoxic side
202 effect of MTX in different tissues and organs at the same or different markers.

203 ACKNOWLEDGEMENTS

204 Thanks to all the peer reviewers for their opinions and suggestions. We would like to thank Prof. Dr. Ahmet Hilmi Yücel for
205 his contributions to this study.

206 COMPETING INTERESTS

207 We wish to confirm that there are no conflicts of interest associated with this publication and there has been no significant
208 financial support for this work that could have influenced its outcome.

209 AUTHORS' CONTRIBUTIONS

210 Idea, design, collection of resources by: AGK, MK, EŞ, MGB, application by: AGK, MK, EŞ, MGB, analysis and
211 interpretation of results and literature by: AGK, MK, EŞ, MGB written and reviewed by: AGK and MGB.

212 CONSENT

213 In this study, human hepatocyte (CRL-11233) cells obtained from the American Type Culture Collection Organization
214 (ATCC) were used.

215 ETHICAL APPROVAL

216 Approval was obtained from Çukurova University Faculty of Medicine Clinical Ethics Committee (approval number: 104/9).
217 All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee
218 and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of
219 Helsinki.

220 REFERENCES

- 221 1. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in
222 patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013;144:1419-
223 1425.e1413.
- 224 2. Helal MG, Said E. Tranilast attenuates methotrexate-induced renal and hepatic toxicities: Role of apoptosis-
225 induced tissue proliferation. *J Biochem Mol Toxicol.* 2020;34(5):e22466. doi: 10.1002/jbt.22466.
- 226 3. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with
227 methotrexate: a randomized, double-blind, placebo-controlled trial. *Br J Dermatol* 2006; 154:1169-74.
- 228 4. Jolivet jj, Cowan KH, Clendennin Nj, Chabner BA. The pharmacokinetics and clinical use of methotrexate. *N Engl*
229 *j med* 1983; 309: 1094-104.
- 230 5. Chen YX, Lv WG, Chen HZ, Ye f, Xie X. Methotrexate induces apoptozis of human choriocarcinoma cell line JAR
231 via a mitachondrial pathway. *Eur j Obstet Gynecol Reprod Biol.* 2009;143(2):107-11.

- 243 6. Ginnani EH, Brewer EJ, Kuzima N, Shakiov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT,
244 Zemel LS. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USAUSSR double blind placebo
245 controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Study Group. *N*
246 *Engl J Med* 1992; 326:1043-9.
- 247 7. Bangert CA, Costner MI. Methotrexate in dermatology. *Dermatol Ther* 2007;(4):216-28.
- 248 8. Van Ede AE, Laan RFJM, Rood MJ. Effects of folic or folinic acid supplementation on the toxicity and efficacy of
249 methotrexate in rheumatoid arthritis. *Arthritis Rheumatism*. 2001;44:1515-24.
- 250 9. Armağan I, Bayram D, Candan IA, Yiğit A, Çelik E, Armağan HH, et al. Effects of pentoxifylline and alpha lipoic
251 acid on methotrexate-induced damage in liver and kidney of rats. *Environmental Toxicology And Pharmacology*.
252 2015;39:1122-31.
- 253 10. Guais A, Baronzio GF, Sanders E, Campion F, Mainini C, Fiorentini G, et al. Adding a combination of
254 hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor
255 development: experimental results and case report. *Invest New Drugs*. 2012;30:200-11. *Indian Journal of*
256 *Gastroenterology*. 2011;30:38-40.
- 257 11. Dadhania VP, Tripathi DN, Vikram A, Ramarao P, Jena GB. Intervention of lipoic acid ameliorates methotrexate-
258 induced oxidative stress and genotoxicity: a study in rat intestine. *Chemico Biological Interactions*. 2010;183: 85-
259 97.
- 260 12. Muralikrishnan G, Amalan Stanley V, Sadasivan Pillai K. Dual role of vitamin C on lipid profile and combined
261 application of cyclophosphamide, methotrexate and 5-fluorouracil treatment in fibrosarcoma-bearing rats. *Cancer*
262 *Lett*. 2001 Aug 28; 169(2):115-20.
- 263 13. Jahovic N, Cevik H, Sehirli AO, Yeğen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal
264 oxidative injury in rats. *J Pineal Res*. 2003 May; 34(4):282-7.
- 265 14. Famurewaa AC, Folawiyob AM, Enohnyaketb EB, Azubuike-Osue SO, Abid I, Obajee SG, Famurewaf OA.
266 Beneficial role of virgin coconut oil supplementation against acute methotrexate chemotherapy-induced oxidative
267 toxicity and inflammation in rats. *Integrative Medicine Research*. 2018; 7: 257-63.
- 268 15. Cline A, Jorizzo JL. Does daily folic acid supplementation reduce methotrexate efficacy? *Dermatology Online*
269 *Journal*. 2017; 11(6): 1-3.
- 270 16. Kirbas A, Cure MC, Kalkan Y, Cure E, Tumkaya L, Sahin OZ, Yuce S, Kizilkaya B, Pergel A. Effect of infliximab
271 on renal injury due to methotrexate in rat. *Iranian Journal of Kidney Diseases*. 2015; 9(3): 221-9.
- 272 17. Samdanci ET, Huz M, Ozhan O, Tanbek K, Pamukcu E, Akatli AN, Parlakpınar H. Cytoprotective effects of
273 molsidomine against methotrexate-induced hepatotoxicity: an experimental rat study. *Drug Design Development*
274 *and Therapy*. 2019; 13: 13-21.
- 275 18. Kalantaria H, Asadmasjedib N, Abyazb MR, Mahdaviniaç M, Mohammadtaghvaeid N. Protective effect of inulin on
276 methotrexate- induced liver toxicity in mice. *Biomedicine & Pharmacotherapy*. 2019;110:943-50.
- 277 19. Rizk F, Saadeny AA, Dawood L, Elkaliny HH. Metformin ameliorated methotrexate-induced hepatorenal toxicity in
278 rats in addition to its antitumor activity: Two birds with one stone. *Journal of Inflammation Research*. 2018;
279 11:421-9.
- 280 20. Amirfakhrian H, Abedi SM, Sadeghi H, Azizi S, Hosseinimehr SJ. The use of 99mTc-phytate for assessment the
281 protective effect of vitamin E against hepatotoxicity induced by methotrexat in rat. *Nuclear Medicine Review*.
282 2018;21(1):8-13.
- 283 21. Hasan H, Ismail H, El-Orfali Y, Khawaja G. Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis
284 and its protective effect against methotrexate inducedhepatic toxicity. *BMC Complementary and Alternative*
285 *Medicine*. 2018;18(337):1-12.

- 286 22. Montasser AOS, Saleh H, Ahmed-Farid OA, Saad A, Marie MAS. Protective effects of balanites aegyptiaca
287 extract, melatonin and ursodeoxycholic acid against hepatotoxicity induced by methotrexate in male rats. Asian
288 Pacific Journal of Tropical Medicine. 2017;10(6):557-65.
- 289 23. Abo-Haded HM, Elkablawy MA, Al-johani Z, Al-ahmadi O, El-Agamy DS. Hepatoprotective effect of sitagliptin
290 against methotrexate induced liver toxicity. Plos One. 2017; 12(3):1-16.
- 291 24. Hagag AA, Elgamsy MA, El-Asy HM, Mabrouk MM. Protective role of silymarin on hepatic and renal toxicity
292 induced by mtx based chemotherapy in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis.
293 2016;8:1-9.
- 294 25. Moghadam AR, Tutunchi S, Namvaran-Abbas-Abad A, Yazdi M, Bonyadi F, Mohajeri D, Mazani M, Marzban H,
295 Łos MJ, Ghavami S. Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative
296 stress. BMC Complementary and Alternative Medicine. 2015;15(246):1-13.
- 297 26. Malayeri A, Badparva R, Mombeini MA, Khorsandi L, Goudarzi M. Naringenin: a potential natural remedy against
298 methotrexate-induced hepatotoxicity in rats. Drug and Chemical Toxicology. 2020;1-8.
- 299 27. Bell JA, Kenelly JJ. Conjugated linoleic acid enriched milk: a designer milk with potential. Advances in Dairy
300 Technology. 2001;13:213-28.
- 301 28. Griffiths GO, Cowan RA, Grigor KM, Uscinska BM, Sydes M, Russell M. BA08: An open-label, single-arm,
302 nonrandomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of
303 the urinary tract. PLOS ONE. 2019; 14(1): 1-9.
- 304 29. Wippel B, Gundle KR, Dang T, Paxton J, Bubalo J, Stork L, Fu R, Ryan CW, Davis LE. Safety and efficacy of
305 high-dose methotrexate for osteosarcoma in adolescents compared with young adults. Cancer Medicine.
306 2019;8:111-6.
- 307 30. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine.
308 2019;86(3):301-7.
- 309 31. Daggulli M, Dede O, Utangac MM, Bodakci MN, Hatipoglu NK, Penbegul N, Sancaktutar AA, Bozkurt Y, Türkçü
310 G, Yüksel H. Protective effects of carvacrol against methotrexate-induced testicular toxicity in rats. Int J Clin Exp
311 Med. 2014;7(12):5511-6.
- 312 32. Mercantepe T, Kalkan Y, Tumkaya L, Sehitoglu İ, Mercantepe F, Yıldırım S. Protective effects of tumor necrosis
313 factor alpha inhibitors on methotrexate-induced pancreatic toxicity. Adv Clin Exp Med. 2018;27(6):715-20.
- 314 33. Yang Y, Wang X, Tian J, Wang Z. Renal function and plasma methotrexate concentrations predict toxicities in
315 adults receiving high-dose methotrexate. Med Sci Monit. 2018;24:7719-26.
- 316 34. Forster VJ, McDonnell A, Theobald R, McKay JA. Effect of methotrexate/vitamin B12 on DNA methylation as a
317 potential factor in leukemia treatment-related neurotoxicity. Epigenomics. 2017; 9(9): 1205-18.
- 318 35. Guyenet SJ, Carlson SE. Increase in adipose tissue linoleic acid of us adults in the last half century. 2015; 6: 660-
319 4.
- 320 36. Ge Z, Wang C, Zhang J, Li X, Hu J. Tempol protects against acetaminophen induced acute hepatotoxicity by
321 inhibiting oxidative stress and apoptosis. Front Physiol. 2019;10:660. doi: 10.3389/fphys.2019.00660.
- 322 37. Shahroudi MJ, Mehri S, Hosseinzadeh H. Anti-aging effect of nigella sativa fixed oil on d-galactose-induced aging
323 in mice. J Pharmacopuncture. 2017;20(1):29-35. doi: 10.3831/KPI.2017.20.006.
- 324 38. Zhang ZD, Yang YJ, Liu XW, Qin Z, Li SH, Li JY. The protective effect of aspirin eugenol ester on paraquat-
325 induced acute liver injury rats. Front Med (Lausanne). 2020;7:589011. doi: 10.3389/fmed.2020.589011.

- 326 39. Ramachandran A, Lebofsky M, Weinman SA, Jaeschke H. The impact of partial manganese superoxide
327 dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during
328 acetaminophen hepatotoxicity. *Toxicol Appl Pharmacol.* 2011;251(3):226-33. doi: 10.1016/j.taap.2011.01.004.
- 329 40. Kouam AF, Yuan F, Njayou FN, He H, Tsayem RF, Oladejo BO, Song F, Moundipa PF, Gao GF. Induction of
330 Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from *Khaya grandifoliola* C.DC Protect L-02 Hepatocytes
331 against Acetaminophen-Induced Hepatotoxicity. *Front Pharmacol.* 2017;8:653. doi: 10.3389/fphar.2017.00653.
- 332 41. Wu H, Zhang G, Huang L, Pang H, Zhang N, Chen Y, Wang G. Hepatoprotective Effect of Polyphenol-Enriched
333 Fraction from *Folium Microcos* on Oxidative Stress and Apoptosis in Acetaminophen-Induced Liver Injury in Mice.
334 *Oxid Med Cell Longev.* 2017;1-14:3631565. doi: 10.1155/2017/3631565.
- 335 42. Duan Y, Duan J, Feng Y, Huang X, Fan W, Wang K, Ouyang P, Deng Y, Du Z, Chen D, Geng Y, Yang S.
336 Hepatoprotective activity of vitamin e and metallothionein in cadmium-induced liver injury in ctenopharyngodon
337 idellus. *Oxid Med Cell Longev.* 2018;1-12:9506543. doi: 10.1155/2018/9506543.
- 338 43. Hamed SS, Al-Yhya NA, El-Khadragy MF, Al-Olayan EM, Alajmi RA, Hassan ZK, Hassan SB, Abdel Moneim AE.
339 The protective properties of the strawberry (*fragaria ananassa*) against carbon tetrachloride-induced
340 hepatotoxicity in rats mediated by anti-apoptotic and upregulation of antioxidant genes expression effects. *Front*
341 *Physiol.* 2016;7:325. doi: 10.3389/fphys.2016.00325.
- 342 44. Orazizadeh M, Khorsandi L, Mansouri E, Fakhredini F. The effect of glycyrrhizin acid on Bax and Bcl2 expression
343 in hepatotoxicity induced by Titanium dioxide nanoparticles in rats. *Gastroenterol Hepatol Bed Bench.* 2020
344 *Spring*;13(2):168-176.
- 345 45. Słowikowski BK, Drzewiecka H, Malesza M, Mądry I, Sterzyńska K, Jagodziński PP. The influence of conjugated
346 linoleic acid on the expression of peroxisome proliferator-activated receptor- γ and selected apoptotic genes in
347 non-small cell lung cancer. *Mol Cell Biochem.* 2020;466(1-2):65-82. doi: 10.1007/s11010-020-03689-8.
- 348 46. Amini E, Asadpour R, Roshangar L, Jafari-Joozani R. Effect of linoleic acid supplementation on in vitro
349 maturation, embryo development and apoptotic related gene expression in ovine. *Int J Reprod Biomed.*
350 2016;14(4):255-62.
- 351 47. Mondal A, Guria T, Maity TK, Bishayee A. A Novel Tetraenoic Fatty Acid Isolated from *Amaranthus spinosus*
352 Inhibits Proliferation and Induces Apoptosis of Human Liver Cancer Cells. *Int J Mol Sci.* 2016 Sep
353 22;17(10):1604. doi: 10.3390/ijms17101604.
- 354 48. Lu G, Zhang G, Zheng X, Zeng Y, Xu Z, Zeng W, Wang K. c9, t11- conjugated linoleic acid induces HCC cell
355 apoptosis and correlation with PPAR- γ signaling pathway. *Am J Transl Res.* 2015;7(12):2752-63.
- 356 49. Shen MC, Zhao X, Siegal GP, Desmond R, Hardy RW. Dietary stearic acid leads to a reduction of visceral
357 adipose tissue in athymic nude mice. *PLoS One.* 2014;9(9):e104083. doi: 10.1371/journal.pone.0104083.
- 358 50. Qi R, Yang F, Huang J, Peng H, Liu Y, Liu Z. Supplementation with conjugated linoleic acid decreases pig back fat
359 deposition by inducing adipocyte apoptosis. *BMC Vet Res.* 2014 Jun 26;10:141. doi: 10.1186/1746-6148-10-141.
- 360 51. Soliman MM, Aldhahrani A, Alkhedaide A, Nassan MA, Althobaiti F, Mohamed WA. The ameliorative impacts of
361 *Moringa oleifera* leaf extract against oxidative stress and methotrexate-induced hepato-renal dysfunction. *Biomed*
362 *Pharmacother.* 2020 Aug;128:110259. doi: 10.1016/j.biopha.2020.110259.
- 363 52. Kalantari H, Asadmasjedi N, Abyaz MR, Mahdavinia M, Mohammadtaghvaei N. Protective effect of inulin on
364 methotrexate- induced liver toxicity in mice. *Biomed Pharmacother.* 2019;110:943-950. doi:
365 10.1016/j.biopha.2018.11.144.
- 366 53. Tabatabaei Mirakabad FS, Khoramgah MS, Tahmasebinia F, et al. The Effect of Low-Level Laser Therapy and
367 Curcumin on the Expression of LC3, ATG10 and BAX/BCL2 Ratio in PC12 Cells Induced by 6-Hydroxide
368 Dopamine. *J Lasers Med Sci.* 2020;11(3):299-304. doi:10.34172/jlms.2020.50.

369
370
371

54. Yazdani Z, Mehrabanjoubani P, Rafiei A, Biparva P, Kardan M. Combined Effect of Cold Atmospheric Plasma and Curcumin in Melanoma Cancer. *Biomed Res Int.* 2021;2021:1969863. Published 2021 Nov 16. doi:10.1155/2021/1969863.

372